Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 68

1.

Alzheimer's disease: cerebrolysin and nanotechnology as a therapeutic strategy.

Sharma HS, Muresanu DF, Sharma A.

Neurodegener Dis Manag. 2016 Dec;6(6):453-456. No abstract available.

PMID:
27827552
2.

Pathophysiology of Blood-Brain Barrier in Brain Injury in Cold and Hot Environments: Novel Drug Targets for Neuroprotection.

Sharma HS, Muresanu DF, Lafuente JV, Nozari A, Patnaik R, Skaper SD, Sharma A.

CNS Neurol Disord Drug Targets. 2016;15(9):1045-1071.

PMID:
27592625
3.

Nanowired Drug Delivery Across the Blood-Brain Barrier in Central Nervous System Injury and Repair.

Sharma A, Menon P, Muresanu DF, Ozkizilcik A, Tian ZR, Lafuente JV, Sharma HS.

CNS Neurol Disord Drug Targets. 2016;15(9):1092-1117.

PMID:
27538949
4.

Credibility judgments in web page design - a brief review.

Selejan O, Muresanu DF, Popa L, Muresanu-Oloeriu I, Iudean D, Buzoianu A, Suciu S.

J Med Life. 2016 Apr-Jun;9(2):115-9. Review.

5.

The ubiquitin proteasomal system: a potential target for the management of Alzheimer's disease.

Gadhave K, Bolshette N, Ahire A, Pardeshi R, Thakur K, Trandafir C, Istrate A, Ahmed S, Lahkar M, Muresanu DF, Balea M.

J Cell Mol Med. 2016 Jul;20(7):1392-407. doi: 10.1111/jcmm.12817. Review.

6.

Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial.

Muresanu DF, Heiss WD, Hoemberg V, Bajenaru O, Popescu CD, Vester JC, Rahlfs VW, Doppler E, Meier D, Moessler H, Guekht A.

Stroke. 2016 Jan;47(1):151-9. doi: 10.1161/STROKEAHA.115.009416.

7.

Plasmatic markers for early diagnostic and treatment decisions in ischemic stroke.

Stanca DM, Mărginean IC, Sorițău O, Mureșanu DF.

J Med Life. 2015;8 Spec Issue:21-5. Review.

8.

Low-frequency rTMS in patients with subacute ischemic stroke: clinical evaluation of short and long-term outcomes and neurophysiological assessment of cortical excitability.

Blesneag AV, Slăvoacă DF, Popa L, Stan AD, Jemna N, Isai Moldovan F, Mureșanu DF.

J Med Life. 2015 Jul-Sep;8(3):378-87.

9.

Sleep Deprivation-Induced Blood-Brain Barrier Breakdown and Brain Dysfunction are Exacerbated by Size-Related Exposure to Ag and Cu Nanoparticles. Neuroprotective Effects of a 5-HT3 Receptor Antagonist Ondansetron.

Sharma A, Muresanu DF, Lafuente JV, Patnaik R, Tian ZR, Buzoianu AD, Sharma HS.

Mol Neurobiol. 2015 Oct;52(2):867-81. doi: 10.1007/s12035-015-9236-9.

PMID:
26133300
10.

Nanowired Delivery of Growth Hormone Attenuates Pathophysiology of Spinal Cord Injury and Enhances Insulin-Like Growth Factor-1 Concentration in the Plasma and the Spinal Cord.

Muresanu DF, Sharma A, Lafuente JV, Patnaik R, Tian ZR, Nyberg F, Sharma HS.

Mol Neurobiol. 2015 Oct;52(2):837-45. doi: 10.1007/s12035-015-9298-8.

PMID:
26126514
11.

Nanoparticles Exacerbate Both Ubiquitin and Heat Shock Protein Expressions in Spinal Cord Injury: Neuroprotective Effects of the Proteasome Inhibitor Carfilzomib and the Antioxidant Compound H-290/51.

Sharma HS, Muresanu DF, Lafuente JV, Sjöquist PO, Patnaik R, Sharma A.

Mol Neurobiol. 2015 Oct;52(2):882-98. doi: 10.1007/s12035-015-9297-9.

PMID:
26126513
12.

Exacerbation of Methamphetamine Neurotoxicity in Cold and Hot Environments: Neuroprotective Effects of an Antioxidant Compound H-290/51.

Sharma HS, Kiyatkin EA, Patnaik R, Lafuente JV, Muresanu DF, Sjöquist PO, Sharma A.

Mol Neurobiol. 2015 Oct;52(2):1023-33. doi: 10.1007/s12035-015-9252-9.

PMID:
26111626
13.

PLGA Nanoparticles Loaded Cerebrolysin: Studies on Their Preparation and Investigation of the Effect of Storage and Serum Stability with Reference to Traumatic Brain Injury.

Ruozi B, Belletti D, Sharma HS, Sharma A, Muresanu DF, Mössler H, Forni F, Vandelli MA, Tosi G.

Mol Neurobiol. 2015 Oct;52(2):899-912. doi: 10.1007/s12035-015-9235-x.

PMID:
26108180
14.

GFAP and antibodies against NMDA receptor subunit NR2 as biomarkers for acute cerebrovascular diseases.

Stanca DM, Mărginean IC, Sorițău O, Dragoș C, Mărginean M, Mureșanu DF, Vester JC, Rafila A.

J Cell Mol Med. 2015 Sep;19(9):2253-61. doi: 10.1111/jcmm.12614.

15.

A retrospective, multi-center cohort study evaluating the severity- related effects of cerebrolysin treatment on clinical outcomes in traumatic brain injury.

Muresanu DF, Ciurea AV, Gorgan RM, Gheorghita E, Florian SI, Stan H, Blaga A, Ianovici N, Iencean SM, Turliuc D, Davidescu HB, Mihalache C, Brehar FM, Mihaescu AS, Mardare DC, Anghelescu A, Chiparus C, Lapadat M, Pruna V, Mohan D, Costea C, Costea D, Palade C, Bucur N, Figueroa J, Alvarez A.

CNS Neurol Disord Drug Targets. 2015;14(5):587-99.

PMID:
25924999
16.

Drainage of cerebral abscesses prior to valve replacement in stable patients with acute left-sided infective endocarditis.

Molnar A, Beyer R, Florian S, Muresanu DF, Trifan C, Muresan I, Sacui D, Scridon T, Balanescu RN.

CNS Neurol Disord Drug Targets. 2015;14(4):534-9.

PMID:
25801842
17.
18.

Reading beyond the glance: eye tracking in neurosciences.

Popa L, Selejan O, Scott A, Mureşanu DF, Balea M, Rafila A.

Neurol Sci. 2015 May;36(5):683-8. doi: 10.1007/s10072-015-2076-6. Review.

PMID:
25604577
19.

Effects and tolerability of betahistine in patients with vestibular vertigo: results from the Romanian contingent of the OSVaLD study.

Băjenaru O, Roceanu AM, Albu S, Zainea V, Pascu A, Georgescu MG, Cozma S, Mărceanu L, Mureşanu DF.

Int J Gen Med. 2014 Dec 4;7:531-8. doi: 10.2147/IJGM.S71015.

20.

Development of in vivo drug-induced neurotoxicity models.

Sharma HS, Menon P, Lafuente JV, Muresanu DF, Tian ZR, Patnaik R, Sharma A.

Expert Opin Drug Metab Toxicol. 2014 Dec;10(12):1637-61. doi: 10.1517/17425255.2014.970168. Review.

PMID:
25311945
Items per page

Supplemental Content

Loading ...
Support Center